Pediatric Cancer Pipeline Insights Report 2016 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets (
has announced the addition of the “Pediatric
Cancer-Pipeline Insights, 2016”
report to their offering.

Pediatric Cancer-Pipeline Insights, 2016 provides in depth insights on
the pipeline drugs and their development activities around the Pediatric
Cancer. The report covers the product profiles in various stages of
development including Discovery, Pre-clinical, IND, Phase I, Phase II,
Phase III and Preregistration.

Report covers the product clinical trials information and other
development activities including technology, licensing, collaborations,
acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and
dormant drugs that have gone inactive over the years for Pediatric

The report also assesses the Pediatric Cancer therapeutics by
Monotherapy, Combination products, molecule type and Route of


  • The report provides competitive pipeline landscape of Pediatric Cancer
  • The report provides pipeline products under drug profile section which
    includes product description, MOA, licensors & collaborators,
    development partner and chemical information
  • Coverage of the Pediatric Cancer pipeline on the basis of target, MOA,
    route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics
    development for Pediatric Cancer and also provide company profiling
  • The report also gives the information of dormant and discontinued
    pipeline projects
  • Pipeline products coverage based on various stages of development
    ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development and molecule type

Key Topics Covered:

  1. Pediatric Cancer Overview
  2. Pediatric Cancer Pipeline Therapeutics
  3. Pediatric Cancer Therapeutics under Development by Companies
  4. Pediatric Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Pediatric Cancer Phase II Products
  7. Pediatric Cancer Phase I and IND Filed Products
  8. Pediatric Cancer Discovery and Pre-Clinical Stage Products
  9. Pediatric Cancer – Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Pediatric Cancer – Discontinued Products
  15. Pediatric Cancer – Dormant Products
  16. Companies Involved in Therapeutics Development for Pediatric Cancer

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals,